bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.2150
+0.0150 (7.50%)
At close: May 13, 2025, 4:00 PM
0.2100
-0.0050 (-2.33%)
Pre-market: May 14, 2025, 8:52 AM EDT
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2024. The number of employees decreased by 18 or -24.00% compared to the previous year.
Employees
57
Change (1Y)
-18
Growth (1Y)
-24.00%
Revenue / Employee
$164,246
Profits / Employee
-$158,594
Market Cap
3.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BIAF News
- 6 days ago - Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer - Business Wire
- 6 days ago - WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering - PRNewsWire
- 6 days ago - bioAffinity Technologies Announces Closing of $3.25 Million Offering - Business Wire
- 7 days ago - WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering - PRNewsWire
- 7 days ago - bioAffinity Technologies Announces Pricing of $3.25 Million Offering - Business Wire
- 26 days ago - bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - Business Wire
- 6 weeks ago - bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - Business Wire
- 7 weeks ago - Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer - Business Wire